Re: Guru P. Sonpavde. Role of Adjuvant Therapy in Current Perioperative Immunotherapy-based Trials in Bladder Cancer: A Justified Standard. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2025.05.008
Re: Guru P. Sonpavde. Role of Adjuvant Therapy in Current Perioperative Immunotherapy-based Trials in Bladder Cancer: A Justified Standard. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2025.05.008. // European Urology Focus. – URL: https://www.sciencedirect.com/science/article/pii/S2405456925001889?dgcid=rss_sd_all
Re: Guru P. Sonpavde. Role of Adjuvant Therapy in Current Perioperative Immunotherapy-based Trials in Bladder Cancer: A Justified Standard. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2025.05.008. European Urology Focus. https://www.sciencedirect.com/science/article/pii/S2405456925001889?dgcid=rss_sd_all
“Re: Guru P. Sonpavde. Role of Adjuvant Therapy in Current Perioperative Immunotherapy-based Trials in Bladder Cancer: A Justified Standard. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2025.05.008.” European Urology Focus.
@article{article107490,
title = {Re: Guru P. Sonpavde. Role of Adjuvant Therapy in Current Perioperative Immunotherapy-based Trials in Bladder Cancer: A Justified Standard. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2025.05.008},
journal = {European Urology Focus},
url = {https://www.sciencedirect.com/science/article/pii/S2405456925001889?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...